

# Effective connectivity of emotion and cognition under psilocybin

Devon Stoliker<sup>1,2\*</sup>, Leonardo Novelli<sup>1,2</sup>, Franz X. Vollenweider<sup>3</sup>, Gary F. Egan<sup>1,2</sup>, Katrin H. Preller<sup>3+</sup>,  
Adeel Razi<sup>1,2,4,5+</sup>

<sup>1</sup>Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC

<sup>2</sup> Monash Biomedical Imaging, Monash University, Clayton, VIC

<sup>3</sup> Department of Psychiatry, Psychotherapy & Psychosomatics, Psychiatric University Hospital Zurich,  
Zurich, Switzerland

<sup>4</sup> Wellcome Centre for Human Neuroimaging, UCL, London, United Kingdom

<sup>5</sup> CIFAR Azrieli Global Scholars Program, CIFAR, Toronto, Canada

+ Joint Senior Authors

## Abstract

Classic psychedelics alter sense of self and patterns of self-related thought. These changes are hypothesised to underlie their therapeutic efficacy across internalising pathologies such as addiction and depression. Using resting-state functional MRI images from a randomised, double blinded, placebo-controlled clinical trial of 24 healthy adults under 0.215mg/kg psilocybin, we investigated how psilocybin modulates the effective connectivity between resting state networks and the amygdala that are involved in the appraisal and regulation of emotion and association with clinical symptoms. The networks included the default mode network (DMN), salience network (SN) and central executive network (CEN). Psilocybin decreased top-down effective connectivity from the resting state networks to the amygdala and decreased effective connectivity within the DMN and SN, while the within CEN effective connectivity increased. Effective connectivity changes were also associated with altered emotion and meaning under psilocybin. Our findings identify changes to cognitive-emotional connectivity associated with the subjective effects of psilocybin and the attenuation of the amygdala signal as a potential biomarker of psilocybin's therapeutic efficacy.

30 Keywords – fMRI, psychedelics, resting state connectivity, dynamic causal modelling, psilocybin,  
31 emotion, cognition, amygdala

32

### 33 **Introduction**

34

35 Psilocybin, the main active compound of so-called magic mushrooms, is a serotonergic psychedelic that  
36 has been used throughout history in religious and medical rituals to alter consciousness (Carod-Artal,  
37 2015; Nichols, 2016). It belongs to a larger group of substances such as ayahuasca (DMT) and mescaline  
38 that share molecular binding kinetics to serotonergic 5-HT receptors distributed throughout the brain  
39 (Nichols, 2012). Agonism of the 5-HT<sub>2A</sub> receptor is primarily responsible for psychedelic subjective  
40 effects that can cause powerful changes to subjective experience (Vollenweider et al 1998; (Kometer et  
41 al., 2012) Kometer et al. 2013; Preller et al. 2017; Kraehenmann et al. 2017). Psychedelics can also  
42 produce feelings of subjective wellbeing (Hirschfeld & Schmidt, 2020) and profound changes in self-  
43 awareness and perception, including visual hallucinations and synaesthesia, and a sense of transcendence  
44 of time and space (Studerus, Gamma, & Vollenweider, 2010; Swanson, 2018; Wittmann et al., 2007;  
45 (Stoliker, Egan, Friston, & Razi, 2022). Altered (self-)perception and self-awareness are unique effects of  
46 serotonergic psychedelics and may involve an experience of ego dissolution, defined as a loss of self-  
47 boundaries and sense of unity between the self and the environment (Stoliker, Egan, Friston, & Razi,  
48 2021; Stoliker, Egan, Friston, et al., 2022) Lebedev et al., 2015). Although complete ego dissolution is  
49 rare at the medium dose potency used in clinical trials, several studies have found that overall blissful ego  
50 dissolution (as measured by the total mystical score or oceanic self-boundlessness) is associated with  
51 better long-term outcomes in healthy subjects (Griffiths et al., 2011) and reduced symptoms of depression  
52 (Griffiths et al., 2016; Roseman, Nutt, & Carhart-Harris, 2018; Ross et al., 2016) and addiction  
53 (Bogenschutz et al., 2015; Garcia-Romeu, Griffiths, & Johnson, 2014).

54

55

56 Depression has been linked to a fundamental sense of disconnectedness (Northoff, 2007), which may be  
57 ameliorated by psychedelics. Studies have found reduced depression scores and improved wellness  
58 associated with enhanced the subjective sense of connectedness following an acute psychedelic  
59 experience (R. L. Carhart-Harris et al., 2018; Watts, Day, Krzanowski, Nutt, & Carhart-Harris, 2017;  
60 Watts et al., 2022). Research findings indicate a strong correlation between ratings of psychological  
61 insight one day after a session with psilocybin and decreases in depression four weeks later (Alan K.  
62 Davis et al., 2021). Reduced depression may also be mediated by increased cognitive and psychological  
63 flexibility after psychedelics (A. K. Davis, Barrett, & Griffiths, 2020; Doss et al., 2021). These findings  
64 suggest that the long-term benefits of psychedelics for mental health may result from modulation of the  
65 regulation of emotions and cognitive processing (Duerler, Vollenweider, & Preller, 2022; Franz X.  
66 Vollenweider & Preller, 2020). Moreover, the acute psychedelic experience appears to be crucial to these  
67 changes.

68  
69 The amygdala is a bilateral subcortical region composed of many subnuclei that integrate cortical and  
70 thalamic sensory inputs (Babaev, Piletti Chatain, & Krueger-Burg, 2018). Its primary function is to  
71 respond to the emotional significance of stimuli and regulate arousal (Alexander et al., 2021; Bonnet et  
72 al., 2015). For example, presentations of positive or negative emotional stimuli, such as physical threats,  
73 elicit activation of the amygdala (Alexander et al., 2021; Garavan, Pendergrass, Ross, Stein, & Risinger,  
74 2001; Hobin, Goosens, & Maren, 2003; Weymar & Schwabe, 2016). The amygdala also responds to  
75 cognitive-emotional significance. For example, when personal beliefs are threatened (Kaplan, Gimbel, &  
76 Harris, 2016). This demonstrates self-beliefs can condition and regulate amygdala emotional responses.  
77 Similarly, complex emotions such as shame are associated with the amygdala and can be diminished by  
78 its damage (Piretti et al., 2020). Emotional empathy is also associated with amygdala function (Geng et  
79 al., 2018; Hillis, 2014; Marsh et al., 2013), and has been reported to be modified by psilocybin (Pokorny,  
80 Preller, Kometer, Dziobek, & Vollenweider, 2017; Preller et al., 2015).

81

82 Further associations between emotional and behaviour regulation and the amygdala are demonstrated by  
83 damage to the amygdala which affects decision-making (Gupta, Koscik, Bechara, & Tranel, 2011) and  
84 memory (Adolphs, Tranel, & Denburg, 2000). Amygdala hyperactivation is also a marker of stress and  
85 anxiety, which are implicated across internalising disorders for which psychedelics demonstrate efficacy  
86 (Nutt & Carhart-Harris, 2020); Koob & Volkow, 2010; Luo, Xue, Shen, & Lu, 2013; Menon, 2011).  
87 Emotional regulation depends on top-down and bottom-up modulation of the amygdala (McRae, Misra,  
88 Prasad, Pereira, & Gross, 2012; Ochsner et al., 2009) and appears to be altered by psychedelics. For  
89 example, healthy adults administered psilocybin show reduced effective connectivity from the amygdala  
90 to the primary visual cortex coincident with reduced threat processing (Kraehenmann et al., 2015)  
91 (Kraehenmann et al., 2016). The semisynthetic psychedelic drug lysergic diethylamide acid (LSD) has  
92 also been shown to dampen the amygdala response to fearful stimuli (Mueller et al., 2017; Barrett, Doss,  
93 Sepeda, Pekar, & Griffiths, 2020). Furthermore, decreased amygdala activity has been correlated with  
94 positive mood under psilocybin lasting up to one month (Kraehenmann et al., 2015; Barrett et al., 2020).  
95 However, subjects with treatment resistant depression imaged one day post-treatment show increased  
96 amygdala responses to stimuli with psilocybin as well as improvements in depressive symptoms  
97 (Roseman, Demetriou, Wall, Nutt, & Carhart-Harris, 2018; Barrett et al., 2020). Together, these results  
98 suggest a change in amygdala connectivity under the acute influence of psychedelics may be a biological  
99 mechanism underwriting the beneficial, mood-enhancing effects of psilocybin.

100

101 The amygdala is integrated with cognition through top-down projections from midline cortical regions  
102 (Etkin et al., 2011; Kraehenmann et al., 2016; Robinson et al., 2013). These projections are thought to  
103 underlie the perception and intensity of positive and negative emotions (Bonnet et al., 2015) and abnormal  
104 connectivity of this circuitry underlies psychopathological conditions such as anxiety disorders (Menon,  
105 2011). Amygdala connectivity changes that involve frontal cortical regions have been found in several  
106 studies suggesting psilocybin modulates the top-down control of limbic regions involved in emotional  
107 processing (Bernasconi et al., 2014; Mertens et al., 2020; Mueller et al., 2017; Barrett et al., 2020). Changes

108 to the amygdala and cortical regions are sustained well beyond the half-life of psilocybin and may last up  
109 to one month post administration (Barrett, Doss, Sepeda, Pekar, & Griffiths, 2020), demonstrating the  
110 lasting neural changes in association with increased positive affect.

111  
112 Emotion is a flexible, dynamic and functionally integrated with cognitive regions of the brain (Lindquist,  
113 Satpute, Wager, Weber, & Barrett, 2016). The function of cortical regions linked to amygdala are related  
114 to the sense of self, self-referential cognition, cognitive appraisal, and emotional regulation. For example,  
115 limbic-cortical dysregulation has been reported to impact mood regulation (Zeng et al., 2012). The  
116 changes to cortical regions under the acute effects of psychedelics may modulate subcortical regions that  
117 disrupt affective responses that may potentially support therapeutic responses.

118  
119 Here we investigate to what extent psilocybin modulates the relationship of cognitive-emotional networks  
120 interactions that may be relevant for therapeutic outcomes. We investigated amygdala connectivity to  
121 regions that form frontal and anterior nodes of distinct large-scale resting-state networks (RSNs). RSNs  
122 are determined by temporally correlated activation across spatially distributed brain regions and serve  
123 essential functions in cognition (Fox et al., 2005; Raichle, 2015). The RSN regions of particular relevance  
124 to this study are abundant in 5-HT<sub>2A</sub> receptors (Saulin, Savli, & Lanzenberger, 2012; R. L. Carhart-  
125 Harris & Friston, 2019) and include the default mode network (DMN), central executive network (CEN)  
126 and the salience network (SN).

127  
128 The DMN integrates internal and external information to perform self-referential mental activity involved  
129 in forming self-beliefs (Amey, Leitner, Liu, & Forbes, 2022; Tompson, Chua, & Kitayama, 2016) and is  
130 composed of the medial prefrontal cortex (mPFC) and posterior cingulate cortex (PCC) central hub  
131 regions. Increased DMN connectivity with the amygdala is observed in depressed subjects (Sheline  
132 Yvette et al., 2009) and has been associated with symptoms such as rumination (Cooney, Joormann,  
133 Eugène, Dennis, & Gotlib, 2010). In contrast, decreased coupling of the central hub regions of the DMN

134 was reported in association with the reduced mind wandering of advanced meditation practitioners  
135 (Judson A. Brewer et al., 2011). Similar decoupling was found acutely (Carhart -Harris et al 2012) and  
136 two days after psilocybin (R. L.; Smigielski, Scheidegger, Kometer, & Vollenweider, 2019). We  
137 hypothesise reduced interactions between the amygdala and DMN and reduced within-DMN connectivity  
138 may underpin an altered sense of self and self-related emotion under psychedelic subjective effects and  
139 these subjective effects can be measured using the blissful state (emotion) and changed meaning of  
140 percept subscales of the 5D-ASC (Studerus, Gamma, & Vollenweider, 2010). Connectivity changes,  
141 particularly those associated with subjective changes, may serve as a biomarker of connectivity that may  
142 have therapeutic properties.

143  
144 The central executive network (CEN) is a RSN involved in thinking, planning, and controlling attention  
145 (Andrews-Hanna et al., 2014; Menon, 2011). Abnormal CEN function is associated with mental health in  
146 various cognitive disorders. For example, reduced CEN activity has been associated with chronic  
147 schizophrenia and depression (Leptourgos et al., 2020; Menon, 2011) and increased CEN-amygdala  
148 connectivity was observed in association with catastrophising of chronic pain (Jiang et al., 2016). The  
149 central hub regions of the CEN are the dorsolateral prefrontal cortex (dorsolateral PFC) and the lateral  
150 posterior parietal cortex (lateral PPC). The dorsolateral PFC serves a primary role in regulating emotion  
151 (Underwood et al., 2021) and was associated with worry in healthy adults and individuals with  
152 generalised anxiety (Paulesu et al., 2010; Servaas et al., 2014; Jamieson, Harrison, Razi, & Davey, 2022).  
153 Under psychedelics, a number of brain mapping studies suggest psychedelics increase the global  
154 connectivity and flexibility of CEN connectivity that may be associated with subjective emotional  
155 changes (Luppi et al., 2021; Tagliazucchi et al., 2016); Lord et al., 2019).

156  
157 The salience network (SN) is a cognitive RSN involved in the detection of salient features in the  
158 environment and disengages task-irrelevant activity associated with the DMN, for example during  
159 daydreaming. The SN's cardinal regions are the dorsal anterior cingulate cortex (dorsal ACC) and anterior

160 insula (AI). Expanded network compositions of the SN also include the amygdala which may be  
161 important for the initial emotional appraisal of salient stimuli. Overactive salience attributed to  
162 hyperactivity of the AI or amygdala stimuli is a feature of various forms of psychopathology (Menon,  
163 2011) and the AI is important to integrate affective and cognitive signals that influence interoceptive  
164 responses related to psychosomatic symptoms and anxiety and depression (Paulus, 2006; Terasawa,  
165 Shibata, Moriguchi, & Umeda, 2013 ;Wiebking et al., 2015). The dorsal ACC region of the SN is  
166 activated in response to social pain (Rotge et al., 2015) that has been associated with changes in self-  
167 processing (Smigielski et al. 2019; Smigielski et al., 2020) as well as reduced sense of social exclusion  
168 under psilocybin (Preller et al., 2016; Preller et al., 2015). Observations under psilocybin have also shown  
169 reduced SN integrity (Lebedev et al., 2015) and changes to effective connectivity from the SN to the  
170 DMN under LSD (Stoliker, Novelli, et al., 2021). Psychedelics may alter salience functions that select the  
171 pre-reflective channels of attention and modulate amygdala connectivity involved in emotional attention  
172 and appraisal (Kapur, 2003; Stoliker, Egan, et al., 2021).

173

## 174 **Results:**

175

176 *Network effective connectivity change with the amygdala under psilocybin*

177

178 Participants underwent resting-state fMRI scans 70 minutes post oral administration of psilocybin.

179 Effective connectivity between the amygdala and the DMN, SN and CEN and brain-behaviour analysis

180 was performed at the group level using the framework of parametric empirical Bayes (PEB, see

181 supplementary material for details). The reported results for effective connectivity and brain-behaviour

182 analysis used a threshold of posterior probability  $> 0.99$  for inference with very strong evidence. Those


183 connections and associations not reported did not exceed this threshold. For more statistical details, see

184 Supplementary Table 1.

185

186 i) *Change of DMN effective connectivity to the amygdala under psilocybin*

187 Group level effective connectivity strength between regions of the DMN and amygdala showed decreased  
188 self-inhibition of the PCC (effect size = -0.21) and decreased effective connectivity from the PCC with  
189 the left amygdala (effect size = -0.33 Hz) compared to placebo.



190

191 *Fig 1. Default mode network effective connectivity change under psilocybin 70 minutes post-*  
192 *administration. Connections show changes in effective connectivity compared to placebo. Values display*  
193 *effect sizes (posterior expectations) of connections in Hz (except the inhibitory self-connections which are*  
194 *log-scaled). Values linked to subjective effects represent their associations with effective connectivity and*  
195 *represent normalized beta ( $\beta$ ) coefficients. All results are for posterior probability > 0.99 (amounting to*  
196 *very strong evidence).*

197

198 ii) *Change of CEN effective connectivity to the amygdala under psilocybin*


199

200 Several changes in effective connectivity were found, whose interplay is captured schematically in Fig. 2.

201 Specifically, group level effective connectivity strength between regions of the CEN and amygdala showed



202 increased self-inhibition of the right dorsolateral PFC (effect size = +0.17), left dorsolateral PFC (effect  
 203 size = +0.19) and decreased self-inhibition of the left lateral PPC (effect size = -0.2), compared to placebo.  
 204 Effective connectivity from the left lateral PPC to the left amygdala decreased (effect size = -0.22 Hz) and  
 205 increased from right lateral PPC to the right dorsolateral PFC (effect size = +0.2 Hz) and decreased to the  
 206 right amygdala (effect size = -0.39 Hz). Left dorsolateral PFC effective connectivity to the right amygdala  
 207 decreased (effect size = -0.16 Hz) and increased to the left lateral PPC (effect size = +0.23 Hz), while right  
 208 dorsolateral PFC increased to the left dorsolateral PFC (effect size = +0.15 Hz) and the right amygdala  
 209 increased to the left lateral PPC (effect size = +0.28 Hz), compared to placebo.




210  
 211 *Fig 2. Central executive network effective connectivity change under psilocybin 70 minutes post-*  
 212 *administration. Values display effect sizes (posterior expectations) of connections in Hz (except the*  
 213 *inhibitory self-connections which are log-scaled). Values linked to subjective effects represent their*  
 214 *associations with effective connectivity and represent normalized  $\beta$  coefficients. All results are for posterior*  
 215 *probability > 0.99.*

216  
 217 *iii) Change of SN effective connectivity to the amygdala under psilocybin*

218

219 Group-level effective connectivity analysis showed increased self-inhibition of the right AI  
220 (effect size = +0.23) and bilateral amygdala (effect size = +0.16 (right) and +0.31 (left)) and decreased  
221 effective connectivity from the dorsal ACC to right amygdala (effect size = -0.19 Hz) and from left AI to  
222 the right amygdala (effect size = -0.24 Hz) compared to placebo (Fig 3).  
223



224  
225 *Fig 3. Salience network effective connectivity change under psilocybin 70 minutes post-administration.*  
226 *Connections show changes in effective connectivity compared to placebo. Values display effect sizes*  
227 *(posterior expectations) of connections in Hz (except the inhibitory self-connections which are log-scaled).*  
228 *Values linked to subjective effects represent their associations with effective connectivity and represent*  
229 *normalized  $\beta$  coefficients. All results are for posterior probability > 0.99.*

230  
231 *Brain-behaviour associations*

232 *i) Behavioural associations to DMN-amygdala effective connectivity change under psilocybin*

233  
234 The brain-behaviour analysis showed negative association between self-connectivity of PCC and blissful  
235 state ( $\beta$  coefficient = - 0.06), negative association between effective connectivity from PCC to left

236 amygdala and changed meaning of percept ( $\beta$  coefficient = - 0.04), and negative association between  
237 effectivity from left amygdala to PCC and changed meaning of percept ( $\beta$  coefficient = - 0.06). See Fig  
238 1.

239  
240 *ii) Behavioural associations to CEN-amygdala effective connectivity change under psilocybin*

241  
242 The brain-behaviour analysis showed positive association between effective connectivity from left lateral  
243 PPC to right amygdala and blissful state ( $\beta$  coefficient = + 0.03), positive association between effective  
244 connectivity from right DLPFC to left DLPFC and changed meaning of percept ( $\beta$  coefficient = + 0.03),  
245 negative association between self-connectivity of left lateral PPC to changed meaning of percept ( $\beta$   
246 coefficient = - 0.04) ad blissful state ( $\beta$  coefficient = - 0.06), and positive association between effective  
247 connectivity from left DLPFC to left lateral PPC and changed meaning of percept ( $\beta$  coefficient = + 0.07).  
248 See Fig 2.

249  
250 *iii) Behavioural associations to SN-amygdala effective connectivity change under psilocybin*

251  
252 The brain-behaviour analysis showed negative association between effective connectivity from left AI to  
253 right amygdala and changed meaning of percept ( $\beta$  coefficient = - 0.06). See Fig 3.

254

## 255 **Discussion:**

256

257 To investigate the influence of psilocybin on the interaction between emotion and cognition, we measured  
258 connectivity changes between the amygdala and selected RSNs. These networks serve functions in  
259 selfhood and cognition and are composed of regions linked to the regulation and experience of emotion.  
260 Our results demonstrate increased inhibitory effective connectivity from cortical regions to the amygdala  
261 under psilocybin. For example, we showed this change in connectivity from the PCC, left dorsolateral

262 PFC, bilateral lateral PPC, dorsal ACC, and left AI. These results suggest cognitive resources do not  
263 recruit the amygdala under psilocybin, and this modulation of top-down connectivity was related to  
264 subjective effects of psilocybin.

265

266 Examination of the DMN-amygdala connectivity changes under psychedelics did not find effective  
267 connectivity change involving the mPFC, which has been frequently cited in association with emotion,  
268 such as emotional valence (Willinger et al., 2019; Underwood, Tolmeijer, Wibroe, Peters, & Mason,  
269 2021). However, examination of the PCC, which orients information towards the self (Andrews-Hanna,  
270 Smallwood, & Spreng, 2014; J. A. Brewer, Garrison, & Whitfield-Gabrieli, 2013 ; Qin & Northoff,  
271 2011), and amygdala revealed connectivity changes and behavioural associations under psilocybin. PCC  
272 and amygdala effective connectivity change was bidirectional and accompanied by reduced PCC self-  
273 inhibition, which indicates increased synaptic gain or its sensitivity to inputs. The increased PCC synaptic  
274 gain was associated with the subjective experience of blissful state, and PCC bidirectional inhibition with  
275 the left amygdala was associated with changed meaning of percepts. Our findings suggest inhibition  
276 between the amygdala and PCC may be an important connectivity change underlying altered meaning  
277 (i.e., everyday things gained symbolic, strange, or emotional meaning), that, in turn, may contribute to the  
278 change in self-awareness. Our findings also indicate PCC decreased inhibition facilitates blissful feelings.  
279 These changes may reflect reduced top-down cognitive control associated with loss of self-referential  
280 processing that is experienced as a dissolution of self-boundaries and align with the proposed role of the  
281 PCC in self-referential processing (Brewer, Garrison, & Whitfield-Gabrieli, 2013; Qin & Northoff, 2011)  
282 as well as previous evidence of PPC change associated to the dissolution of self-boundaries under  
283 psychedelics (Muthukumaraswamy et al., 2013). For example, previous findings found PCC self-  
284 inhibition under LSD, and the PCC's association with diminished self-representation in social interaction,  
285 feelings of self and self-other processing under psychedelics (Preller et al., 2017; Preller et al., 2019;  
286 Preller et al., 2018; Stoliker, Novelli, et al., 2022).

287

288 Left dorsolateral PFC and left lateral PPC inhibition to the amygdala was also observed and is situated  
289 within the CEN. Connectivity in this network is believed to underlie the evaluative aspect of thought, with  
290 the dorsolateral PFC playing a central role in emotional regulation. However, the observed increased top-  
291 down inhibition of this connectivity to the amygdala was not associated with subjective effects assessed  
292 with the 5D-ASC scale. Instead, the pattern of activity in this network is open to interpretation. One  
293 characterisation of the observed activity may be its resemblance to hyper-frontality, which is associated  
294 with worry and anxiety (Park, Wood, Bondi, Del Arco, & Moghaddam, 2016), and acute psychosis (F. X.  
295 Vollenweider et al., 1997). There is also evidence that CEN connectivity is increased, and the amygdala  
296 connectivity is decreased, during cognitive control strategies (Herwig et al., 2007; Herwig, Kaffenberger,  
297 Jäncke, & Brühl, 2010). However, links between CEN activity and behaviour are suggested to be task and  
298 context-dependent (Borders, 2020) and subjects in this study reported nominal anxiety, see Supplementary  
299 Material. An alternative interpretation is that the observed connectivity pattern between regions of the CEN  
300 constitutes an increase in evaluative thought processes and may be linked to re-appraisal. For example,  
301 increased CEN and decreased amygdala activity of healthy adults was observed to increase during emotion-  
302 introspection, while increased CEN and increased amygdala activity was associated with self-reflection  
303 (Herwig et al., 2010). This literature may help explain the activation differences in the amygdala observed  
304 between healthy adults under psychedelics and clinical populations in the days after psychedelics.  
305 Moreover, increased CEN and decreased amygdala activity align our findings with connectivity underlying  
306 emotion-introspection. Although the introspection of healthy adults in this imaging study was not assumed,  
307 psilocybin experiences are commonly related to emotional introspection. Further evidence demonstrating  
308 the therapeutic capacity of increased intrinsic CEN connectivity is presented in association with resilience  
309 (Miller Gregory et al., 2018). Moreover, positive self-appraisal has been associated with increased CEN  
310 and amygdala connectivity (Brühl, Rufer, Kaffenberger, Baur, & Herwig, 2014), which may relate to self-  
311 reflection in the days after psilocybin administration. This evidence indicates the increased CEN  
312 connectivity and CEN top-down inhibition to the amygdala as a connectivity change that relates to the  
313 therapeutic potential of psilocybin for the revision of beliefs and it warrants further investigation.

314

315 Although we expect re-evaluation of thought under psychedelics to be influenced by the context (i.e., the  
316 mindset of participants and environmental setting), measured subjective effects associated with CEN  
317 connectivity changes are detectable in the imaging environment. For example, increased connectivity from  
318 the left dorsolateral PFC to the left lateral PPC and connectivity between the bilateral dorsolateral PFC was  
319 associated with changed meaning of percepts. Moreover, connectivity from the left dorsolateral PFC and  
320 right AMG to the left lateral PPC and decreased left lateral PPC self-inhibition were associated with both  
321 blissful state and the changed meaning of percepts. The lateral PPC inhibition to the amygdala may suggest  
322 its decoupling from the amygdala limits the sensory and interoceptive information to the amygdala, while  
323 the left amygdala synaptic gain increased. These results demonstrate nuanced modulation of the CEN-  
324 amygdala connectivity that align with previous reports of functional desegregation and expanded access to  
325 wider dynamics of brain states made available under psychedelics (Atasoy et al., 2017; Barnett,  
326 Muthukumaraswamy, Carhart-Harris, & Seth, 2019; R. L. Carhart-Harris & Nutt, 2017; A. K. Davis et al.,  
327 2020; Matias, Lottem, Dugué, & Mainen, 2017; Stoliker, Egan, & Razi, 2022; Tagliazucchi, Carhart-Harris,  
328 Leech, Nutt, & Chialvo, 2014; Watts & Luoma, 2020). These connectivity changes may be important to  
329 psilocybin's therapeutic potential that can be targeted to facilitate cognitive-emotional changes.

330

331 The ACC and AI serve essential functions in salience detection, and the integration of these regions with  
332 the amygdala may underwrite pathologically enhanced salience detection (Menon, 2011). These regions'  
333 inhibition of the right amygdala suggests their role in salience detection is diminished under psilocybin,  
334 which may be therapeutic for internalising disorders. Notably, previous literature found that psilocybin  
335 acutely reduced mainly the response in the right amygdala to negative stimuli, which may reflect  
336 “decentering” from one's emotion and thought that may facilitate reappraisal (Malinowski, 2013).  
337 However, inhibited salience detection also aligns with positive symptoms in schizophrenia (i.e.,  
338 hallucinations and delusions) (Menon, 2011). At higher doses, psychedelics can induce a psychotic-like  
339 state in some individuals (F. X. Vollenweider, Vollenweider-Scherpenhuyzen, Babler, Vogel, & Hell,

340 1998), that may be related to the effect of serotonergic psychedelics on salience detection (Preller et al.,  
341 2017). However, psychotic-like behavioural outcomes rarely occur in a controlled clinical setting (Johnson,  
342 Richards, & Griffiths, 2008; Studerus, Gamma, Kometer, & Vollenweider, 2012; Studerus et al., 2010).

343  
344 Previous research shows that increased functional connectivity between the AI and amygdala is associated  
345 with relapse of addiction in preclinical studies (Venniro et al., 2017) and behavioural habituation in healthy  
346 adults (Denny et al., 2014). Increased effect connectivity of this link has been associated with depression  
347 in clinical populations (Kandilarova, Stoyanov, Kostianev, & Specht, 2018). The AI inhibition to the  
348 amygdala was associated with changed meaning of percepts that suggests it may be associated with  
349 therapeutic behavioural change. Previous task-based research shows reduced dorsal ACC activity in  
350 association with blunted response to social exclusion under psilocybin (Preller et al., 2015). Although our  
351 findings did not associate subjective effects with this connection, dorsal ACC-related inhibition aligns with  
352 the inhibition of social pain (Preller et al., 2016; Preller et al., 2015) and previous findings of this circuit  
353 implicate top-down inhibition in the resolution of emotional conflict (Etkin, Egner, Peraza, Kandel, &  
354 Hirsch, 2006). DCM also estimated increased self-inhibition in the bilateral amygdala and rAI, suggesting  
355 reduced synaptic gain of the regions. LSD produced similar results that demonstrated hypo-connectivity of  
356 the right insula (Preller et al., 2018). However, the changes we observed were not associated with the  
357 measured psychedelic subjective effects.

358  
359 Taken together, our results suggest that psilocybin attenuates the recruitment of the amygdala. This  
360 connectivity contributes to the altered meaning of percepts and subjective emotion. Diminished amygdala  
361 activation has been related to emotional regulation (Herwig et al., 2019) and may alter the patterns of  
362 connectivity that condition emotional, cognitive and self-reflective responses. Psilocybin induced change  
363 to the RSNs that we observed generally aligns with previous literature that shows the increased flexibility  
364 and transition of network states under psychedelics, as well as nimble and flexible brain networks are  
365 instrumental to positive emotion and affect (Alexander et al., 2021). Therefore, the RSNs reduced



366 connectivity to the amygdala and altered within-RSN effective connectivity that we observed may be  
367 important aspects of the subjective effects and emotional-cognitive connectivity changes that therapeutic  
368 applications capitalise upon to encourage revision of beliefs.

369  
370 Our endeavour to investigate interactions between emotion and cognition in a healthy population under  
371 psilocybin has several limitations. For example, our analysis would benefit from MRI scans taken before  
372 and after the administration of psilocybin. Exploring links between emotional and associative connectivity  
373 also involves deciding network configuration and regions for analysis. Regions such as the ventral striatum,  
374 precuneus, and parahippocampus and further subregions of the PFC and ACC may also be valuable for  
375 examining the links between emotion and cognition (Underwood et al., 2021). Furthermore, each region  
376 selected as part of the network may be determined differently depending on the method of identification of  
377 the region. Further standardisation of this process is complex for anatomical reasons and remains under  
378 debate. The processing pipeline, participant sample and dose of psilocybin can also strongly impact the  
379 reliability of results. Participants were given lower doses than currently used in clinical studies of  
380 depression and substance dependence disorders. Therefore, connectivity dynamics may be dissimilar at a  
381 higher dose. Data sets at higher doses may provide improved inference and more nuanced characterisation  
382 of the neural dynamics of interest. We also overlooked the influence of numerous neurotransmitter systems  
383 involved in emotion that may interact with altered serotonin transmission. These interactions may provide  
384 a novel line of inquiry to understand psychedelic therapeutic effects.

385  
386 Other limitations in the methods and analysis include the use of global signal regression and the limited  
387 temporal resolution. Temporal resolution is likely to be significant in the study of emotion. For example,  
388 the time course of emotion may present distinct contributions of brain regions involved in valence and  
389 arousal (Alexander et al., 2021). Modalities with temporal specificity capable of resolving insight and  
390 emotional change, such as EEG or MEG, which can also be analysed using DCM, are needed in future



391 investigations. Furthermore, studies using task-based fMRI paradigms can induce activations in specific  
392 emotion and cognition related brain regions (Brühl et al., 2014; Herwig et al., 2007; Herwig et al., 2010).

393

394 The generalisability of our results to clinical populations is limited by the use of a small healthy adult  
395 sample and the congruence between our results and previous findings. Previous research indicates

396 psychedelics may globally increase bottom-up connectivity (R. Carhart-Harris, Kaelen, & Nutt, 2014; R.

397 L. Carhart-Harris & Friston, 2019; Swanson, 2018). For example, evidence of thalamic connectivity to the

398 cortex supports this view (Müller, Dolder, Schmidt, Liechti, & Borgwardt, 2018; Preller et al., 2019).

399 However, decoupling between limbic regions and the cortex has also been identified (Robin L. Carhart-

400 Harris et al., 2016; Lebedev et al., 2015). Our findings that identified increased bottom-up connectivity

401 from the right amygdala to the left lateral PPC align with the latter studies. As psychedelic research

402 advances, we suggest examination of multiple limbic regions and their subnuclei connectivity to the cortex.

403 This may reveal more precise and nuanced dynamics between the subcortex and cortex underlie previously

404 theorised global patterns. For example, recent investigations have demonstrated spatial specificity of

405 entropic activity and thalamic connectivity associated with psychedelic subjective effects (Gaddis et al.,

406 2022). Along these lines, the amygdala is composed of many subnuclei. Its small size, anatomical variability

407 and position deep within the brain presents challenges for noise-to-signal ratio and spatial location in group

408 fMRI analysis, which future imaging and research methods may overcome. Finally, increased excitation

409 among the CEN effective connectivity contrasts with previous analyses, which found a general reduction

410 in associative functional connectivity (Preller et al., 2020). While the global reduction of associative

411 connectivity may help explain experiences of ego dissolution, psychedelic experiences also contain

412 phenomenological richness (Millière, Carhart-Harris, Roseman, Trautwein, & Berkovich-Ohana, 2018).

413 Future research of CEN regions may wish to address the reliability of this effective connectivity and

414 examine links between the CEN, subjective experience, and therapeutic outcomes. Such work may benefit

415 from finer grained emotional and cognitive rating scales.

416

417 In sum, we demonstrated altered within-RSN effective connectivity and reduced top-down RSN-amygdala  
418 effective connectivity associated with emotional and cognitive behavioural changes under psilocybin. The  
419 functional significance of these changes to perceptual processes and psychopathology may be reduced  
420 cognitive control and increased flexibility of these networks and the attenuated modulation of the amygdala  
421 under the acute effects of psilocybin. These changes may enable a mental workspace for therapeutic  
422 emotional and cognitive change. We suggest RSN attenuation of the amygdala as a potential biomarker for  
423 future clinical research investigating the neural correlates of psychedelic therapeutic efficacy. Future work  
424 may also build upon our effective connectivity findings to understand how connectivity underlying emotion  
425 and cognition interact with the therapeutic context to effect patterns of thought and behaviour. These lines  
426 of enquiry can help discern the imperative of the psychedelic subjective experience to therapeutic outcomes  
427 and bridge gaps in our understanding of the relationship between brain connectivity and behaviour.

428

## 429 **Methods**

430

### 431 *Participants*

432 The data analysed in this paper were collected as part of a previous study (registered at ClinicalTrials.gov  
433 (NCT03736980)), which is reported in (Preller et al., 2020) and was approved by the Cantonal Ethics  
434 Committee of Zurich. Twenty-four subjects (12 males and 11 females; mean age = 26.3 y; range = 20–40  
435 y; 1 subject did not complete the study) were recruited through advertisements at universities in Zurich,  
436 Switzerland. All participants were deemed healthy after screening for medical history, physical  
437 examination, blood analysis, and electrocardiography. The Mini-International Neuropsychiatric Interview  
438 (MINI-SCID) (Sheehan et al., 1998), the DSM-IV fourth edition self-rating questionnaire for Axis-II  
439 personality disorders (SCID-II) (Fydrich, Renneberg, Schmitz, & Wittchen, 1997), and the Hopkins  
440 Symptom Checklist (SCL-90-R) (Franke, 2002) were used to exclude subjects with present or previous  
441 psychiatric disorders or a history of major psychiatric disorders in first-degree relatives. Participants were  
442 asked to abstain from prescription and illicit drug use two weeks prior to first testing and throughout the

443 duration of the study, and abstain from alcohol use 24 hours prior to testing days. Urine tests and self-report  
444 questionnaires were used to verify the absence of drug and alcohol use. Urine tests were also used to exclude  
445 pregnancy. Further exclusion criteria included left-handedness, poor knowledge of the German language,  
446 cardiovascular disease, history of head injury or neurological disorder, history of alcohol or illicit drug  
447 dependence, MRI exclusion criteria, including claustrophobia, and previous significant adverse reactions  
448 to a hallucinogenic drug. All participants provided written informed consent statements in accordance with  
449 the declaration of Helsinki before participation in the study. Subjects received written and oral descriptions  
450 of the study procedures, as well as details regarding the effects and possible risks of drug treatment.

451

#### 452 *Design*

453 A double blind, randomised, placebo-controlled, cross-over study was performed. Testing days occurred  
454 two weeks apart and participants were orally administered either psilocybin (0.2mg/kg orally) or placebo  
455 (179 mg mannitol and colloidal silicon dioxide (Aerosil) 1 mg. Resting state scans (10 minutes each) were  
456 taken 20, 40 and 70 minutes following administration. However, only scans at 70 minutes during the peak  
457 effects were used in our analysis. Participants were asked to not engage in repetitive thoughts such as  
458 counting and instructed to close their eyes during the resting state scan. Subjective experience was assessed  
459 using the retrospective 5-Dimensions Altered States of Consciousness (5D-ASC) questionnaire.  
460 Participants completed the 5D-ASC 360 min following psilocybin administration, see Supplementary.

461

#### 462 *MRI Data Acquisition and Preprocessing*

463 MRI data were acquired on a Philips Achieva 3T whole-body scanner. A 32-channel receive head coil and  
464 MultiTransmit parallel radio frequency transmission was used. Images were acquired using a whole-brain  
465 gradient-echo planar imaging (EPI) sequence (repetition time, 2,430 ms; echo time, 27 ms; slice thickness,  
466 3 mm; 45 axial slices; no slice gap; field of view,  $240 \times 240 \text{ mm}^2$ ; in-plane resolution,  $3 \times 3 \text{ mm}^2$ ; sensitivity-  
467 encoding reduction factor, 2.0). 265 volumes were acquired per resting state scan resulting in a scan  
468 duration of 10 mins. Additionally, two high-resolution anatomical images (voxel size,  $0.7 \times 0.7 \times 0.7 \text{ mm}^3$ )

469 were acquired using T1-weighted and T2-weighted sequences using 3D magnetization prepared rapid-  
470 acquisition gradient echo sequence (MP-RAGE) and a turbo spin-echo sequence, respectively. See  
471 Supplementary for more details. The acquired images were analysed using SPM12  
472 (<https://www.fil.ion.ucl.ac.uk>).

473 The pre-processing steps of the images consisted of slice-timing correction, realignment, spatial  
474 normalization to the standard EPI template of the Montreal Neurological Institute (MNI), and spatial  
475 smoothing using a Gaussian kernel of 6-mm full-width at half maximum. Head motion was investigated  
476 for any excessive movement. Three subjects were excluded due to head motion and one subject did not  
477 complete the scan at 70 minutes.

478

#### 479 *Independent RSN-AMG DCM models*

480 To reduce model complexity and focus the interpretation of the results on the connections of interest our  
481 analysis investigated independent models of amygdala effective connectivity with the DMN, CEN and SN.

482

#### 483 *Extraction of region coordinates across subjects*

484 Neurosynth, a large-scale automated synthesis of functional neuroimaging data, was used to identify  
485 coordinates composing regions of interest (Yarkoni, Poldrack, Nichols, Van Essen, & Wager, 2011). More  
486 details can be found in Supplementary Material.

487 Networks were composed of cardinal regions constituting core parts of the DMN (Andrews-Hanna,  
488 Reidler, Sepulcre, Poulin, & Buckner, 2010; Dixon et al., 2017), SN and CEN. The DMN and SN  
489 followed the selection of regions in a related investigation by Zhou and colleagues (Zhou et al., 2018) and  
490 all networks were included for their role in consciousness and link to emotion (Alexander et al., 2021;  
491 Borders, 2020; Underwood, Tolmeijer, Wibroe, Peters, & Mason, 2021). Associations between peak  
492 coordinates and cardinal nodes of network regions of interest (ROI) were determined by expert visual  
493 inspection. The MNI coordinates of the selected ROIs are listed in Table 1.

494 A generalized linear model (GLM) was used to regress 6 head motion parameters (3 translation and 3  
495 rotational), white matter and cerebrospinal fluid signals from preprocessed data. One subject was excluded  
496 as no activation was found in one or more regions of interest. We also used global signal regression in our  
497 pre-processing pipeline in line with our previous work (Stoliker, Novelli, et al., 2021). The time series for  
498 each ROI was computed as the first principal component of the voxel activity within a 6 mm radius sphere  
499 centred on the ROI coordinates (as listed in Table 1).

<u>Region</u>	<u>MNI coordinates</u>			<u>Network/System</u>
	x	y	z	
PCC	0	-50	28	DMN
mPFC	0	54	20	DMN
dACC	2	28	22	SN
lAI	-34	19	0	SN
rAI	38	18	0	SN
ldPFC	-46	30	32	CEN
rdPFC	42	37	31	CEN
lIPPC	-22	-62	62	CEN
rl PPC	19	-64	55	CEN
lAMG	-21	-5	-17	Limbic
rAMG	23	-3	-19	Limbic

500

501 *Table 1 Coordinates of regions of interest. The DMN comprised of the posterior cingulate cortex (PCC) and*  
502 *medial prefrontal cortex (mPFC); the SN comprised of the dorsal anterior cingulate cortex (dorsal ACC), left*  
503 *and right anterior insula (lAI/rAI); and the CEN comprised the left and right dorsal lateral prefrontal cortex*  
504 *(ldPFC/rd PFC) and the left and right lateral posterior parietal lobule (lIPPC/rIPPC).*

505

506 *Specification and Inversion of DCM*

507 Three independent fully-connected DCM models were specified for each network and the amygdala using  
508 the eleven ROIs defined in Table 4, without any exogenous inputs. The DCM for each subject was then

509 inverted using spectral DCM (Karl J. Friston, Kahan, Biswal, & Razi, 2014; Razi, Kahan, Rees, & Friston,  
510 2015) to infer the effective connectivity that best explains the observed cross-spectral density for each  
511 subject. This procedure was repeated for each testing condition. The DCM fit to the data using cross spectral  
512 density averaged 90.9% for placebo conditions and 89.8% for psilocybin conditions.

513

#### 514 *Second Level Analysis Using Parametric Empirical Bayes*

515 The effective connectivity inferred by spectral DCM for each subject was taken to the second (group) level  
516 to test hypotheses concerning between-group effects. A general linear model (GLM) was employed to  
517 decompose individual differences in effective connectivity into hypothesised group-average connection  
518 strengths together with unexplained noise. Hypotheses on the group-level parameters are tested within the  
519 parametric empirical Bayes (PEB) framework (K. J. Friston et al., 2016), where both the expected values  
520 and the covariance of the parameters were considered. That is, precise parameter estimates influence the  
521 group-level result more strongly than uncertain estimates, which are down-weighted. Bayesian model  
522 reduction (BMR) is used as an efficient form of Bayesian model selection (K. J. Friston et al., 2016). Please  
523 see supplementary material for further technical details about PEB.

524

#### 525 **Author contributions:**

526 Conceptualization: DS, AR, FXV

527 Methodology: DS, LN, AR

528 Investigation: DS, LN, AR

529 Visualization: DS, LN, AR

530 Supervision: AR

531 Writing—original draft: DS

532 Writing—review & editing: DS, LN, AR, GE, KP, FXV

533

534

535 *References*

- 536 Alexander, R., Aragón, O. R., Bookwala, J., Cherbuin, N., Gatt, J. M., Kahrilas, I. J., . . . Styliadis, C.  
537 (2021). The neuroscience of positive emotions and affect: Implications for cultivating  
538 happiness and wellbeing  
539 . *Neuroscience & Biobehavioral Reviews*, *121*, 220-249.  
540 doi:<https://doi.org/10.1016/j.neubiorev.2020.12.002>
- 541 Andrews-Hanna, J. R., Reidler, J. S., Sepulcre, J., Poulin, R., & Buckner, R. L. (2010). Functional-  
542 anatomic fractionation of the brain's default network. *Neuron*, *65*(4), 550-562.  
543 doi:10.1016/j.neuron.2010.02.005
- 544 Atasoy, S., Roseman, L., Kaelen, M., Kringelbach, M. L., Deco, G., & Carhart-Harris, R. L. (2017).  
545 Connectome-harmonic decomposition of human brain activity reveals dynamical  
546 repertoire re-organization under LSD. *Scientific Reports*, *7*. doi:10.1038/s41598-017-  
547 17546-0
- 548 Barnett, L., Muthukumaraswamy, S. D., Carhart-Harris, R. L., & Seth, A. K. (2019). Decreased  
549 Directed Functional Connectivity in the Psychedelic State. *bioRxiv*, 703660.  
550 doi:10.1101/703660
- 551 Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020). Emotions and brain  
552 function are altered up to one month after a single high dose of psilocybin. *Sci Rep*,  
553 *10*(1), 2214. doi:10.1038/s41598-020-59282-y
- 554 Bernasconi, F., Schmidt, A., Pokorny, T., Kometer, M., Seifritz, E., & Vollenweider, F. X. (2014).  
555 Spatiotemporal brain dynamics of emotional face processing modulations induced by  
556 the serotonin 1A/2A receptor agonist psilocybin. *Cereb Cortex*, *24*(12), 3221-3231.  
557 doi:10.1093/cercor/bht178
- 558 Bonnet, L., Comte, A., Tatu, L., Millot, J.-I., Moulin, T., & Medeiros de Bustos, E. (2015). The role  
559 of the amygdala in the perception of positive emotions: an "intensity detector".  
560 *Frontiers in Behavioral Neuroscience*, *9*(178). doi:10.3389/fnbeh.2015.00178
- 561 Borders, A. (2020). Chapter 9 - Rumination, cognition, and the brain. In A. Borders (Ed.),  
562 *Rumination and Related Constructs* (pp. 279-311): Academic Press.
- 563 Brewer, J. A., Garrison, K. A., & Whitfield-Gabrieli, S. (2013). What about the "Self" is Processed  
564 in the Posterior Cingulate Cortex? *Front Hum Neurosci*, *7*, 647.  
565 doi:10.3389/fnhum.2013.00647
- 566 Brühl, A. B., Rufer, M., Kaffenberger, T., Baur, V., & Herwig, U. (2014). Neural circuits associated  
567 with positive and negative self-appraisal. *Neuroscience*, *265*, 48-59.  
568 doi:10.1016/j.neuroscience.2014.01.053
- 569 Carhart-Harris, R., Kaelen, M., & Nutt, D. (2014). How do hallucinogens work on the brain?  
570 *Psychologist*, *27*(9), 662-665. Retrieved from <Go to ISI>://WOS:000341172000027
- 571 Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., . . . Nutt,  
572 D. J. (2018). Psilocybin with psychological support for treatment-resistant depression:  
573 six-month follow-up. *Psychopharmacology*, *235*(2), 399-408. doi:10.1007/s00213-017-  
574 4771-x
- 575 Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the Anarchic Brain: Toward a Unified  
576 Model of the Brain Action of Psychedelics. *Pharmacological Reviews*, *71*(3), 316-344.  
577 doi:10.1124/pr.118.017160



- 578 Carhart-Harris, R. L., & Nutt, D. J. (2017). Serotonin and brain function: a tale of two receptors.  
579 *Journal of Psychopharmacology*, 31(9), 1091-1120. doi:10.1177/0269881117725915
- 580 Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020). Psychological flexibility mediates the relations  
581 between acute psychedelic effects and subjective decreases in depression and anxiety. *J*  
582 *Contextual Behav Sci*, 15, 39-45. doi:10.1016/j.jcbs.2019.11.004
- 583 Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., . . .  
584 Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive  
585 Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*, 78(5), 481-489.  
586 doi:10.1001/jamapsychiatry.2020.3285
- 587 Dixon, M. L., Andrews-Hanna, J. R., Spreng, R. N., Irving, Z. C., Mills, C., Girn, M., & Christoff, K.  
588 (2017). Interactions between the default network and dorsal attention network vary  
589 across default subsystems, time, and cognitive states. *NeuroImage*, 147, 632-649.  
590 doi:10.1016/j.neuroimage.2016.12.073
- 591 Doss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., . . . Barrett,  
592 F. S. (2021). Psilocybin therapy increases cognitive and neural flexibility in patients with  
593 major depressive disorder. *Translational psychiatry*, 11(1), 574. doi:10.1038/s41398-  
594 021-01706-y
- 595 Duerler, P., Vollenweider, F. X., & Preller, K. H. (2022). A neurobiological perspective on social  
596 influence: Serotonin and social adaptation. *J Neurochem*, 162(1), 60-79.  
597 doi:10.1111/jnc.15607
- 598 Etkin, A., Egner, T., Peraza, D. M., Kandel, E. R., & Hirsch, J. (2006). Resolving Emotional Conflict:  
599 A Role for the Rostral Anterior Cingulate Cortex in Modulating Activity in the Amygdala.  
600 *Neuron*, 51(6), 871-882. doi:<https://doi.org/10.1016/j.neuron.2006.07.029>
- 601 Fox, M. D., Snyder, A. Z., Vincent, J. L., Corbetta, M., Van Essen, D. C., & Raichle, M. E. (2005).  
602 The human brain is intrinsically organized into dynamic, anticorrelated functional  
603 networks. *Proceedings of the National Academy of Sciences of the United States of*  
604 *America*, 102(27), 9673. doi:10.1073/pnas.0504136102
- 605 Franke, G. (2002). *Die Symptom-Checkliste von Derogatis (SCL-90-R) - Deutsche Version -*  
606 *Manual*.
- 607 Friston, K. J., Kahan, J., Biswal, B., & Razi, A. (2014). A DCM for resting state fMRI. *NeuroImage*,  
608 94, 396-407. doi:<https://doi.org/10.1016/j.neuroimage.2013.12.009>
- 609 Friston, K. J., Litvak, V., Oswal, A., Razi, A., Stephan, K. E., van Wijk, B. C. M., . . . Zeidman, P.  
610 (2016). Bayesian model reduction and empirical Bayes for group (DCM) studies.  
611 *NeuroImage*, 128, 413-431. doi:10.1016/j.neuroimage.2015.11.015
- 612 Fydrich, T., Renneberg, B., Schmitz, B., & Wittchen, H. U. (1997). *SKID II. Strukturiertes Klinisches*  
613 *Interview für DSM-IV, Achse II: Persönlichkeitsstörungen. Interviewheft. Eine*  
614 *deutschsprachige, erw. Bearb. d. amerikanischen Originalversion d. SKID-II von: M.B.*  
615 *First, R.L. Spitzer, M. Gibbon, J.B.W. Williams, L. Benjamin, (Version 3/96)*.
- 616 Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., . .  
617 . Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in  
618 depression and anxiety in patients with life-threatening cancer: A randomized double-  
619 blind trial. *Journal of Psychopharmacology*, 30(12), 1181-1197.  
620 doi:10.1177/0269881116675513



- 621 Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011).  
622 Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related  
623 effects. *Psychopharmacology*, 218(4), 649-665. doi:10.1007/s00213-011-2358-5
- 624 Herwig, U., Baumgartner, T., Kaffenberger, T., Brühl, A., Kottlow, M., Schreiter-Gasser, U., . . .  
625 Rufer, M. (2007). Modulation of anticipatory emotion and perception processing by  
626 cognitive control. *NeuroImage*, 37(2), 652-662. doi:10.1016/j.neuroimage.2007.05.023
- 627 Herwig, U., Kaffenberger, T., Jäncke, L., & Brühl, A. B. (2010). Self-related awareness and  
628 emotion regulation. *NeuroImage*, 50(2), 734-741.  
629 doi:10.1016/j.neuroimage.2009.12.089
- 630 Herwig, U., Lutz, J., Scherpiet, S., Scheerer, H., Kohlberg, J., Opialla, S., . . . Brühl, A. B. (2019).  
631 Training emotion regulation through real-time fMRI neurofeedback of amygdala activity.  
632 *NeuroImage*, 184, 687-696. doi:10.1016/j.neuroimage.2018.09.068
- 633 Hirschfeld, T., & Schmidt, T. T. (2020). How does it feel to be on psilocybin? Dose-response  
634 relationships of subjective experiences in humans. *bioRxiv*, 2020.2006.2009.142802.  
635 doi:10.1101/2020.06.09.142802
- 636 Jamieson, A. J., Harrison, B. J., Razi, A., & Davey, C. G. (2022). Rostral anterior cingulate network  
637 effective connectivity in depressed adolescents and associations with treatment  
638 response in a randomized controlled trial. *Neuropsychopharmacology*, 47(6), 1240-1248.  
639 doi:10.1038/s41386-021-01214-z
- 640 Johnson, M., Richards, W., & Griffiths, R. (2008). Human hallucinogen research: guidelines for  
641 safety. In (Vol. 22, pp. 603-620). London, England.
- 642 Kandilarova, S., Stoyanov, D., Kostianev, S., & Specht, K. (2018). Altered Resting State Effective  
643 Connectivity of Anterior Insula in Depression. *Frontiers in Psychiatry*, 9.  
644 doi:10.3389/fpsy.2018.00083
- 645 Kapur, S. (2003). Psychosis as a State of Aberrant Salience: A Framework Linking Biology,  
646 Phenomenology, and Pharmacology in Schizophrenia. *American Journal of Psychiatry*,  
647 160(1), 13-23. doi:10.1176/appi.ajp.160.1.13
- 648 Kometer, M., Schmidt, A., Bachmann, R., Studerus, E., Seifritz, E., & Vollenweider, F. X. (2012).  
649 Psilocybin biases facial recognition, goal-directed behavior, and mood state toward  
650 positive relative to negative emotions through different serotonergic subreceptors. *Biol*  
651 *Psychiatry*, 72(11), 898-906. doi:10.1016/j.biopsych.2012.04.005
- 652 Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., &  
653 Vollenweider, F. X. (2015). Psilocybin-Induced Decrease in Amygdala Reactivity  
654 Correlates with Enhanced Positive Mood in Healthy Volunteers. *Biological Psychiatry*,  
655 78(8), 572-581. doi:10.1016/j.biopsych.2014.04.010
- 656 Lebedev, A. V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015).  
657 Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin.  
658 *Human Brain Mapping*, 36(8), 3137-3153. doi:10.1002/hbm.22833
- 659 Luppi, A. I., Carhart-Harris, R. L., Roseman, L., Pappas, I., Menon, D. K., & Stamatakis, E. A.  
660 (2021). LSD alters dynamic integration and segregation in the human brain.  
661 *NeuroImage*, 227, 117653. doi:<https://doi.org/10.1016/j.neuroimage.2020.117653>
- 662 Malinowski, P. (2013). Neural mechanisms of attentional control in mindfulness meditation.  
663 *Front Neurosci*, 7, 8. doi:10.3389/fnins.2013.00008

- 664 Matias, S., Lottem, E., Dugué, G. P., & Mainen, Z. F. (2017). Activity patterns of serotonin  
665 neurons underlying cognitive flexibility. *eLife*, 6, e20552. doi:10.7554/eLife.20552
- 666 McRae, K., Misra, S., Prasad, A. K., Pereira, S. C., & Gross, J. J. (2012). Bottom-up and top-down  
667 emotion generation: implications for emotion regulation. *Social cognitive and affective*  
668 *neuroscience*, 7(3), 253-262. doi:10.1093/scan/nsq103
- 669 Millière, R., Carhart-Harris, R. L., Roseman, L., Trautwein, F.-M., & Berkovich-Ohana, A. (2018).  
670 Psychedelics, Meditation, and Self-Consciousness. *Frontiers in Psychology*, 9(1475).  
671 doi:10.3389/fpsyg.2018.01475
- 672 Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J., Brookes, M. J., Williams, T. M.,  
673 Erntzoe, D., . . . Nutt, D. J. (2013). Broadband Cortical Desynchronization Underlies the  
674 Human Psychedelic State. *The Journal of Neuroscience*, 33(38), 15171-15183.  
675 doi:10.1523/jneurosci.2063-13.2013
- 676 Northoff, G. (2007). Psychopathology and pathophysiology of the self in depression -  
677 neuropsychiatric hypothesis. *J Affect Disord*, 104(1-3), 1-14.  
678 doi:10.1016/j.jad.2007.02.012
- 679 Nutt, D., & Carhart-Harris, R. (2020). The Current Status of Psychedelics in Psychiatry. *JAMA*  
680 *Psychiatry*. doi:10.1001/jamapsychiatry.2020.2171
- 681 Ochsner, K. N., Ray, R. R., Hughes, B., McRae, K., Cooper, J. C., Weber, J., . . . Gross, J. J. (2009).  
682 Bottom-up and top-down processes in emotion generation: common and distinct neural  
683 mechanisms. *Psychol Sci*, 20(11), 1322-1331. doi:10.1111/j.1467-9280.2009.02459.x
- 684 Park, J., Wood, J., Bondi, C., Del Arco, A., & Moghaddam, B. (2016). Anxiety Evokes  
685 Hypofrontality and Disrupts Rule-Relevant Encoding by Dorsomedial Prefrontal Cortex  
686 Neurons. *The Journal of Neuroscience*, 36(11), 3322-3335. doi:10.1523/jneurosci.4250-  
687 15.2016
- 688 Paulesu, E., Sambugaro, E., Torti, T., Danelli, L., Ferri, F., Scialfa, G., . . . Sassaroli, S. (2010).  
689 Neural correlates of worry in generalized anxiety disorder and in normal controls: a  
690 functional MRI study. *Psychol Med*, 40(1), 117-124. doi:10.1017/s0033291709005649
- 691 Paulus, M. (2006). An Insular View of Anxiety. *Biol.Psychiatry*, 60, 383-387.  
692 doi:10.1016/j.biopsych.2006.03.042
- 693 Pokorny, T., Preller, K. H., Kometer, M., Dziobek, I., & Vollenweider, F. X. (2017). Effect of  
694 Psilocybin on Empathy and Moral Decision-Making. *International Journal of*  
695 *Neuropsychopharmacology*, 20(9), 747-757. doi:10.1093/ijnp/pyx047
- 696 Preller, K. H., Burt, J. B., Ji, J. L., Schleifer, C. H., Adkinson, B. D., Stämpfli, P., . . . Anticevic, A.  
697 (2018). Changes in global and thalamic brain connectivity in LSD-induced altered states  
698 of consciousness are attributable to the 5-HT<sub>2A</sub> receptor. *eLife*, 7, e35082.  
699 doi:10.7554/eLife.35082
- 700 Preller, K. H., Duerler, P., Burt, J. B., Ji, J. L., Adkinson, B., Stämpfli, P., . . . Vollenweider, F. X.  
701 (2020). Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity.  
702 *Biological Psychiatry*, 88(2), 197-207.  
703 doi:<https://doi.org/10.1016/j.biopsych.2019.12.027>
- 704 Preller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stampfli, P., . . .  
705 Vollenweider, F. X. (2017). The Fabric of Meaning and Subjective Effects in LSD-Induced  
706 States Depend on Serotonin 2A Receptor Activation. *Curr Biol*, 27(3), 451-457.  
707 doi:10.1016/j.cub.2016.12.030

- 708 Preller, K. H., Pokorny, T., Kraehenmann, R., Scheidegger, M., Dziobek, I., Staempfli, P., &  
709 Vollenweider, F. X. (2015). The 5-HT<sub>2A/1A</sub> agonist psilocybin reduces social pain and  
710 enhances empathy in healthy volunteers. *European Neuropsychopharmacology*, *25*,  
711 S301-S301. doi:10.1016/s0924-977x(15)30364-3
- 712 Preller, K. H., Razi, A., Zeidman, P., Stämpfli, P., Friston, K. J., & Vollenweider, F. X. (2019).  
713 Effective connectivity changes in LSD-induced altered states of consciousness in  
714 humans. *Proceedings of the National Academy of Sciences*, *116*(7), 2743-2748.  
715 doi:10.1073/pnas.1815129116
- 716 Qin, P., & Northoff, G. (2011). How is our self related to midline regions and the default-mode  
717 network? *NeuroImage*, *57*(3), 1221-1233. doi:10.1016/j.neuroimage.2011.05.028
- 718 Raichle, M. E. (2015). The brain's default mode network. *Annu Rev Neurosci*, *38*, 433-447.  
719 doi:10.1146/annurev-neuro-071013-014030
- 720 Razi, A., Kahan, J., Rees, G., & Friston, K. J. (2015). Construct validation of a DCM for resting  
721 state fMRI. *NeuroImage*, *106*, 1-14.  
722 doi:<https://doi.org/10.1016/j.neuroimage.2014.11.027>
- 723 Roseman, L., Demetriou, L., Wall, M. B., Nutt, D. J., & Carhart-Harris, R. L. (2018). Increased  
724 amygdala responses to emotional faces after psilocybin for treatment-resistant  
725 depression. *Neuropharmacology*, *142*, 263-269.  
726 doi:<https://doi.org/10.1016/j.neuropharm.2017.12.041>
- 727 Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018). Quality of Acute Psychedelic Experience  
728 Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. *Frontiers*  
729 *in Pharmacology*, *8*, 974. doi:10.3389/fphar.2017.00974
- 730 Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., . . . Schmidt, B. L. (2016).  
731 Rapid and sustained symptom reduction following psilocybin treatment for anxiety and  
732 depression in patients with life-threatening cancer: a randomized controlled trial.  
733 *Journal of Psychopharmacology*, *30*(12), 1165-1180. doi:10.1177/0269881116675512
- 734 Rotge, J. Y., Lemogne, C., Hinfray, S., Huguet, P., Grynszpan, O., Tartour, E., . . . Fossati, P.  
735 (2015). A meta-analysis of the anterior cingulate contribution to social pain. *Social*  
736 *cognitive and affective neuroscience*, *10*(1), 19-27. doi:10.1093/scan/nsu110
- 737 Saulin, A., Savli, M., & Lanzenberger, R. (2012). Serotonin and molecular neuroimaging in  
738 humans using PET. *Amino Acids*, *42*(6), 2039-2057. doi:10.1007/s00726-011-1078-9
- 739 Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., . . . Dunbar, G. C.  
740 (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development  
741 and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J*  
742 *Clin Psychiatry*, *59 Suppl 20*, 22-33;quiz 34-57.
- 743 Smigielski, L., Kometer, M., Scheidegger, M., Stress, C., Preller, K. H., Koenig, T., & Vollenweider,  
744 F. X. (2020). P300-mediated modulations in self-other processing under psychedelic  
745 psilocybin are related to connectedness and changed meaning: A window into the self-  
746 other overlap. *Hum Brain Mapp*, *41*(17), 4982-4996. doi:10.1002/hbm.25174
- 747 Stoliker, D., Egan, G., Friston, K., & Razi, A. (2021). Neural Mechanisms and Psychology of  
748 Psychedelic Ego Dissolution. In: PsyArXiv.
- 749 Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022). Neural Mechanisms and Psychology of  
750 Psychedelic Ego Dissolution. *Pharmacological Reviews*, *74*(4), 874.  
751 doi:10.1124/pharmrev.121.000508

- 752 Stoliker, D., Egan, G. F., & Razi, A. (2022). Reduced Precision Underwrites Ego Dissolution and  
753 Therapeutic Outcomes Under Psychedelics. *Frontiers in Neuroscience*, *16*.  
754 doi:10.3389/fnins.2022.827400
- 755 Stoliker, D., Novelli, L., Vollenweider, F. X., Egan, G. F., Preller, K. H., & Razi, A. (2021). Effective  
756 connectivity of LSD-induced ego dissolution. *medRxiv*, 2021.2012.2028.21268391.  
757 doi:10.1101/2021.12.28.21268391
- 758 Stoliker, D., Novelli, L., Vollenweider, F. X., Egan, G. F., Preller, K. H., & Razi, A. (2022). Effective  
759 connectivity of functionally anticorrelated networks under LSD. *Biological Psychiatry*.  
760 doi:10.1016/j.biopsych.2022.07.013
- 761 Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012). Prediction of Psilocybin  
762 Response in Healthy Volunteers. *Plos One*, *7*(2). doi:10.1371/journal.pone.0030800
- 763 Studerus, E., Gamma, A., & Vollenweider, F. X. (2010). Psychometric evaluation of the altered  
764 states of consciousness rating scale (OAV). *Plos One*, *5*(8), e12412-e12412.  
765 doi:10.1371/journal.pone.0012412
- 766 Swanson, L. R. (2018). Unifying Theories of Psychedelic Drug Effects. *Frontiers in Pharmacology*,  
767 *9*(172). doi:10.3389/fphar.2018.00172
- 768 Tagliazucchi, E., Carhart-Harris, R., Leech, R., Nutt, D., & Chialvo, D. R. (2014). Enhanced  
769 repertoire of brain dynamical states during the psychedelic experience. *Human Brain  
770 Mapping*, *35*(11), 5442-5456. doi:10.1002/hbm.22562
- 771 Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., . . .  
772 Carhart-Harris, R. (2016). Increased Global Functional Connectivity Correlates with LSD-  
773 Induced Ego Dissolution. *Current biology: CB*, *26*(8), 1043-1050.  
774 doi:10.1016/j.cub.2016.02.010
- 775 Terasawa, Y., Shibata, M., Moriguchi, Y., & Umeda, S. (2013). Anterior insular cortex mediates  
776 bodily sensibility and social anxiety. *Social cognitive and affective neuroscience*, *8*(3),  
777 259-266. doi:10.1093/scan/nss108
- 778 Underwood, R., Tolmeijer, E., Wibroe, J., Peters, E., & Mason, L. (2021). Networks underpinning  
779 emotion: A systematic review and synthesis of functional and effective connectivity.  
780 *NeuroImage*, *243*, 118486. doi:10.1016/j.neuroimage.2021.118486
- 781 Vollenweider, F. X., Leenders, K. L., Scharfetter, C., Maguire, P., Stadelmann, O., & Angst, J.  
782 (1997). Positron emission tomography and fluorodeoxyglucose studies of metabolic  
783 hyperfrontality and psychopathology in the psilocybin model of psychosis.  
784 *Neuropsychopharmacology*, *16*(5), 357-372. doi:10.1016/s0893-133x(96)00246-1
- 785 Vollenweider, F. X., & Preller, K. H. (2020). Psychedelic drugs: neurobiology and potential for  
786 treatment of psychiatric disorders. *Nature Reviews Neuroscience*, *21*(11), 611-624.  
787 doi:10.1038/s41583-020-0367-2
- 788 Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Babler, A., Vogel, H., & Hell, D.  
789 (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2  
790 agonist action. *Neuroreport*, *9*(17), 3897-3902. doi:10.1097/00001756-199812010-  
791 00024
- 792 Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients' Accounts of  
793 Increased "Connectedness" and "Acceptance" After Psilocybin for Treatment-Resistant  
794 Depression. *Journal of Humanistic Psychology*, *57*(5), 520-564.  
795 doi:10.1177/0022167817709585

- 796 Watts, R., Kettner, H., Geerts, D., Gandy, S., Kartner, L., Mertens, L., . . . Roseman, L. (2022). The  
797 Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self,  
798 others, and world. *Psychopharmacology*. doi:10.1007/s00213-022-06187-5  
799 Watts, R., & Luoma, J. B. (2020). The use of the psychological flexibility model to support  
800 psychedelic assisted therapy. *Journal of Contextual Behavioral Science*, 15, 92-102.  
801 doi:<https://doi.org/10.1016/j.jcbs.2019.12.004>  
802 Wiebking, C., de Greck, M., Duncan, N. W., Tempelmann, C., Bajbouj, M., & Northoff, G. (2015).  
803 Interoception in insula subregions as a possible state marker for depression—an  
804 exploratory fMRI study investigating healthy, depressed and remitted participants.  
805 *Frontiers in Behavioral Neuroscience*, 9. doi:10.3389/fnbeh.2015.00082  
806 Yarkoni, T., Poldrack, R. A., Nichols, T. E., Van Essen, D. C., & Wager, T. D. (2011). Large-scale  
807 automated synthesis of human functional neuroimaging data. *Nature Methods*, 8(8),  
808 665-670. doi:10.1038/nmeth.1635  
809 Zhou, Y., Friston, K. J., Zeidman, P., Chen, J., Li, S., & Razi, A. (2018). The Hierarchical  
810 Organization of the Default, Dorsal Attention and Salience Networks in Adolescents and  
811 Young Adults. *Cereb Cortex*, 28(2), 726-737. doi:10.1093/cercor/bhx307  
812  
813